These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6238932)

  • 1. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    Wise R; Lockley R; Webberly M; Adhami ZN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():75-81. PubMed ID: 6238932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tissue penetration of enoxacin.
    Wise R; Lockley R; Dent J; Webberly M
    Antimicrob Agents Chemother; 1984 Jul; 26(1):17-9. PubMed ID: 6591851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and tissue penetration of norfloxacin.
    Adhami ZN; Wise R; Weston D; Crump B
    J Antimicrob Chemother; 1984 Jan; 13(1):87-92. PubMed ID: 6230344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
    Nakamura S; Kurobe N; Kashimoto S; Ohue T; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):54-60. PubMed ID: 6226241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of enoxacin in elderly patients.
    Wise R; Baker SL; Misra M; Griggs D
    J Antimicrob Chemother; 1987 Mar; 19(3):343-50. PubMed ID: 3471751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
    Wolf R; Eberl R; Dunky A; Mertz N; Chang T; Goulet JR; Latts J
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():63-9. PubMed ID: 6389476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and tissue penetration of orally administered pefloxacin.
    Webberley JM; Andrews JM; Ashby JP; McLeod A; Wise R
    Eur J Clin Microbiol; 1987 Oct; 6(5):521-4. PubMed ID: 3481335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norfloxacin--a review of pharmacology and tissue penetration.
    Wise R
    J Antimicrob Chemother; 1984 May; 13 Suppl B():59-64. PubMed ID: 6234277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tissue penetration of ciprofloxacin.
    Crump B; Wise R; Dent J
    Antimicrob Agents Chemother; 1983 Nov; 24(5):784-6. PubMed ID: 6660852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.